



Spravato (esketamine)

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency:					
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested:			ICD10:		
<input type="checkbox"/> Spravato 28mg nasal spray <input type="checkbox"/> Spravato 56mg dose kit nasal spray <input type="checkbox"/> Spravato 84mg does kit nasal spray					
Directions for use:		Quantity:	Duration of therapy:		
Is this a new start or continuation of therapy?					
<input type="checkbox"/> new start of therapy <input type="checkbox"/> continued therapy					
(if continued therapy) Is there a previous approval on record for the medication requested?					Yes <input type="checkbox"/> No <input type="checkbox"/>
(if continued therapy) Is there documentation your patient has had a beneficial response (for example, a 50% or greater reduction in a depression rating scale score from baseline) with the requested medication?					Yes <input type="checkbox"/> No <input type="checkbox"/>
(if no) Please provide clinical support for continued use of Spravato. Please also note how many doses of Spravato your patient has already received.					
Where will this medication be obtained?					
<input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Other (please specify):			<input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Home Health / Home Infusion vendor		
Facility and/or doctor dispensing and administering medication:					
Facility Name:		State:	Tax ID#:		
Address (City, State, Zip Code):					
Is the patient a candidate for home infusion?					Yes <input type="checkbox"/> No <input type="checkbox"/>
Does the physician have an in-office infusion site?					Yes <input type="checkbox"/> No <input type="checkbox"/>
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?					<input type="checkbox"/> Yes <input type="checkbox"/> No
What is your patient's diagnosis?					
<input type="checkbox"/> Major Depressive Disorder with Acute Suicidal Ideation or Behavior <input type="checkbox"/> Treatment-Resistant Depression <input type="checkbox"/> other (please specify):					
Clinical Information					
This drug requires supportive documentation (chart notes, lab and test results, etc). Supportive documentation for all answers must be attached with this request					
Is Spravato being prescribed by, or in consultation with, a psychiatrist?					Yes <input type="checkbox"/> No <input type="checkbox"/>

Will/Is Spravato be(ing) used with at least ONE oral antidepressant?

Notes: Note: may include, but are not limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), mirtazapine, and bupropion. Selective Serotonin Reuptake Inhibitors [SSRIs] include: Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Sertraline. Serotonin-Norepinephrine Reuptake Inhibitors [SNRIs] include: Desvenlafaxine; Duloxetine; Levomilnacipran; Venlafaxine; Tricyclic Antidepressants include: Amitriptyline; Amoxapine; Clomipramine; Desipramine; Doxepin; Imipramine; Nortriptyline; Protriptyline; Trimipramine.

Yes No

Does your patient have a history of psychosis?

Yes No

(if yes) Does the prescriber believe that the benefits of Spravato outweigh the risks?

Yes No

(if Major Depressive Disorder with Acute Suicidal Ideation or Behavior) Does the patient have major depressive disorder that is considered to be severe, according to the prescriber?

Yes No

(if Treatment-Resistant) Has the patient's risk for abuse of controlled substances been assessed (for example, using the state prescription drug monitoring program [PDMP])? Yes No Not applicable (Missouri only)

(if Treatment-Resistant) Has your patient previously been treated with any other antidepressants for this condition? (check all that apply.)

- Bupropion (Aplenzin, Forfivo XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL)
 Mirtazapine (Remeron, Remeron SolTab)
 serotonin-norepinephrine reuptake inhibitors (SNRIs) (Desvenlafaxine [Khedezla], Desvenlafaxine succinate [Pristiq], Duloxetine [Cymbalta], Levomilnacipran [Fetzima], Venlafaxine [Effexor XR])
 selective serotonin reuptake inhibitors (SSRIs) (Citalopram [Celexa], Escitalopram [Lexapro], Fluoxetine [Prozac], Fluvoxamine, Paroxetine hydrochloride [Paxil, Paxil CR], Paroxetine mesylate [Brisdelle, Pexeva], Sertraline [Zoloft])
 tricyclic antidepressants (TCAs) (Amitriptyline [Elavil], Amoxapine, Clomipramine [Anafranil], Desipramine [Norpramin], Doxepin [Silenor], Imipramine [Tofranil, Tofranil-PM], Nortriptyline [Pamelor], Protriptyline, Trimipramine [Sumontil])
 No none of the above

(if treated previously with classes above) Please include specific drug name(s) and strength(s), date(s) taken and for how long, and what the documented results were of taking each.

Did the patient demonstrate nonresponse (defined as 25% or less improvement in depression symptoms or scores) to at least TWO different antidepressants, each from a different pharmacologic class? Yes No

Was each antidepressant used at therapeutic dosages for at least 6 weeks in the current episode of depression? Yes No

What alternatives have been tried? Please include drug name and documented results of taking each drug, including any intolerances or adverse reactions your patient experienced.

Notes: If yes to all questions, please answer as "all yes"

Additional pertinent information (include alternatives tried, date(s) taken and for how long, and what the documented results were of taking this drug, including any intolerances or adverse reactions your patient experienced):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v091521

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005